stemmacolore
Search

Clinical Trials

Clinical Trials

The intensive clinical activity of the IOV is carried out by hospital and university doctors who use cutting-edge treatment programs, with the most accredited conventional cancer treatments. This clinical activity is flanked and complemented by an equally lively research activity that leads to the acquisition of new knowledge for the progress of medicine and offers the possibility to use innovative experimental therapies as therapeutic alternatives, in particular, in patients in whom conventional drugs have failed or have been found to be poorly effective.

This last aspect is achieved thanks to the continuous participation of IOV in clinical trials, both national and international, which involve the use of non-commercialized medicines that are not available on the Italian market. In addition, the Institute’s medical specialists promote, design and carry out clinical trials that explore possible new indications of drugs already on the market, in order to test new therapeutic strategies and thus offer further possibilities of cure.

All clinical trials, whether promoted by the pharmaceutical industry or by non-profit organizations, are conducted at IOV according to strict ethical, regulatory and quality standards. Before being started, each trial must be approved by the Ethics Committee for clinical trials, in accordance with the regulations on clinical trials, the dictates of good clinical practice (GCP) and the ethical principles indicated in the Helsinki Declaration.

For the patients included in the experimental protocols, the main care reference is the research nurses, who represent a flagship of the scientific activity of the IOV, one of only two Italian centers to have this professional figure.

The levels of research, diagnosis and treatment conducted in the Institute place the IOV among the most accredited cancer centers nationwide.

Studio randomizzato e controllato di fase 3 di IMC-F106C più Nivolumab rispetto a regimi di Nivolumab in partecipanti positivi a HLA A*02:01 con melanoma avanzato non trattato in precedenza (PRISM-MEL-301)

Patologie
Stato
Autorizzato - In attesa di apertura
Codice studio
IMC-F106C-301(PRISM-MEL-301)
Codice EudraCT
2023-505306-42-00
Sponsor/Promotore
Immunocore Limited
Tipologia
Sperimentale
Fase
III
Unità Operativa
Principal Investigator

Identificazione delle caratteristiche immunosoppressori e mediante un approccio integrato di imaging radio-immunologico nei pazienti con metastasi cerebrali da melanoma

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
Mela-Immuno-Imaging
Codice EudraCT
NP
Sponsor/Promotore
IOV
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Studio di fase II, a singolo braccio su trattamento neoadiuvante più adiuvante con cemiplimab nel carcinoma cutaneo a cellule squamose di stadio III, ad alto rischio, resecabile chirurgicamente.

Stato
Attivo - reclutamento chiuso
Codice studio
NEO-CESQ
Codice EudraCT
2019-001469-34
Sponsor/Promotore
Fondazione Melanoma (ONLUS)
Tipologia
Sperimentale
Fase
II
Unità Operativa
Principal Investigator

Studio di fase II, randomizzato, non-comparativo, sulla terapia neoadiuvante più adiuvante con combinazione o sequenza di vemurafenib, cobimetinib e atezolizumab in pazienti con melanoma ad alto rischio, asportabile chirurgicamente con mutazione BRAF o wild type.

Patologie
Stato
Attivo - reclutamento chiuso
Codice studio
NEO-TIM
Codice EudraCT
2018-004841-17
Sponsor/Promotore
Fondazione Melanoma (ONLUS)
Tipologia
Sperimentale
Fase
II
Unità Operativa
Principal Investigator

Combinazione di terapia mirata (encorafenib e binimetinib) seguita da immunoterapia combinata (ipilimumab e nivolumab) a confronto con immediata immunoterapia combinata in pazienti affetti da melanoma non operabile o metastatico con mutazione V600 di BRAF: uno studio randomizzato di fase II condotto dall’EORTC (EBIN)

Patologie
Stato
Attivo - reclutamento chiuso
Codice studio
EORTC-1612-MG
Codice EudraCT
2017-002887-42
Sponsor/Promotore
EORTC
Tipologia
Sperimentale
Fase
II
Unità Operativa
Principal Investigator

Search

Status

Last modified: 06/04/2021 15:13

Scroll to Top